Category Archives: Strategy
By Casey McDonald | Published: November 21, 2014
On Monday, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries. For the fourth time, GSK leads the index with Novo Nordisk taking second. J&J. Novartis, Gilead and Merck KGaA rank three to six with nearly even scores.
By Casey McDonald | Published: November 20, 2014
CytRx announced on Tuesday that FDA gave notice of a partial clinical hold for trials for its oncology candidate aldoxorubicin. The hold results from a reported death of a late-stage cancer patient “who did not qualify to participate in any of the ongoing aldoxorubicin clinical trials, but had received aldoxorubicin under the Company’s expanded access […]
By Tom Norton | Published: November 19, 2014
While flipping through my emails last week, I froze before an image that appeared on my screen. An old Rx colleague had sent me a graph, mapping out the 2014 U.S. sales achieved by Gilead’s Hep C drug, Sovaldi. It was stunning. Take a look:
By Pharm Exec | Published: November 19, 2014
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.
By Casey McDonald | Published: November 12, 2014
Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the R&D industry’s global trade group based in Geneva.